Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Serrano-Villar S, Moreno S.

    Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.

    Frontiers in immunology . 13: 923905-923905.

    [doi:10.3389/fimmu.2022.923905]

  • Casado JL, Haemmerle J, Vizcarra P, Ramirez-Alonso G, Salazar-Tosco A, Romero-Hernandez B, Blasco M, Rodriguez-Dominguez M, Mirabella IG, Vallejo A, Fernandez-Escribano M.

    Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination

    Journal Of Clinical Medicine . 11(12): . Nº de citas: 2

    [doi:10.3390/jcm11123352]

  • Serrano-Villar S, Wu K, Hunt PW, Lok JJ, Ron R, Sainz T, Moreno S, Deeks SG, Bosch RJ.

    Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events.

    EBioMedicine . 80: 104072-104072.

    [doi:10.1016/j.ebiom.2022.104072]

  • Crespillo-Andújar C, Comeche B, Hamer DH, Arevalo-Rodriguez I, Alvarez-Díaz N, Zamora J, Pérez-Molina JA.

    Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.

    PLOS NEGLECTED TROPICAL DISEASES . 16(5): .

    [doi:10.1371/journal.pntd.0010386]

  • Cortés A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, Martin A, Chamorro J, Rosero D, Fernández M, Gion M, Martínez Jáñez N, Soria Rivas A, Alonso Gordoa T, Martínez Delfrade Í, Lage Y, López Miranda E, Olmedo ME, Reguera Puertas P, Gajate P, Molina Cerrillo J, Guerra Alia E, Fuentes Mateos R, Romero B, Rodríguez-Domínguez MJ, Vallejo A, Carrato A.

    Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

    EUROPEAN JOURNAL OF CANCER . 166: 229-239. Nº de citas: 12

    [doi:10.1016/j.ejca.2022.02.017]

  • Torrús-Tendero D, Ramos-Rincón JM, Salvador F, Oliveira I, Llenas-García J, Arsuaga M, Crespillo-Andújar C, Pérez-Molina JA.

    Imported fascioliasis in Spain: Report of 12 cases from the +REDIVI collaborative network (2009-2019).

    TRAVEL MEDICINE AND INFECTIOUS DISEASE . 47: 102286-102286.

    [doi:10.1016/j.tmaid.2022.102286]

  • L?pez-Vélez R, Lebens M, Bundy L, Barriga J, Steffen R.

    Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years.

    TRAVEL MEDICINE AND INFECTIOUS DISEASE . 47: 102293-102293. Nº de citas: 5

    [doi:10.1016/j.tmaid.2022.102293]

  • Castón JJ, Cano A, Pérez-Camacho I, Aguado JM, Carratalá J, Ramasco F, Soriano A, Pintado V, Castelo-Corral L, Sousa A, Fariñas MC, Muñoz P, Abril López De Medrano V, Sanz-Peláez Ó, Los-Arcos I, Gracia-Ahufinger I, Pérez-Nadales E, Vidal E, Doblas A, Natera C, Martínez-Martínez L, Torre-Cisneros J.

    Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 77(5): 1452-1460. Nº de citas: 21

    [doi:10.1093/jac/dkac049]

  • Fortún J.

    Diagnostic and therapeutic approach to fungal pneumonia in the critically ill patient.

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 35 Suppl 1: 97-103. Nº de citas: 2

    [doi:10.37201/req/s01.21.2022]

  • Domínguez-Domínguez L, Rava M, Bisbal O, Lopez-Cortés L, Portilla J, Podzamczer D, Olalla J, Fuster D, Rubio R, Jarrín I, Iribarren JA, Moreno S.

    Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018.

    BMC INFECTIOUS DISEASES . 22(1): 379-379.

    [doi:10.1186/s12879-022-07352-z]

  • Bouza E, Arribas JR, Alejos B, Bernardino JI, Coiras M, Coll P, Del Romero J, Fuster MJ, Górgolas M, Gutiérrez A, Gracia D, Hernando V, Martínez-Picado J, Martínez Sesmero JM, Martínez E, Moreno S, Mothe B, Navarro ML, Podzamczer D, Pulido F, Ramos JT, Ruiz-Mateos E, Suárez García I, Palomo E.

    Past and future of HIV infection. A document based on expert opinion.

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(2): 131-156.

    [doi:10.37201/req/083.2021]

  • Martínez-Sanz J, Vivancos-Gallego MJ, Fernández-Felix BM, Muriel A, Pérez-Elías P, Uranga A, Romero B, Galán JC, Moreno S, Pérez-Elías MJ.

    An Easy-to-Implement Risk Score for Targeted Hepatitis C Virus Testing in the General Population.

    Microbiology spectrum . 10(2): . Nº de citas: 1

    [doi:10.1128/spectrum.02286-21]

  • García-Botella A, García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, Bouza E.

    Booster or additional vaccination doses in patients vaccinated against COVID-19.

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(2): 105-114. Nº de citas: 6

    [doi:10.37201/req/149.2021]

  • García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, Bouza E.

    Pharmacological treatment of COVID-19: an opinion paper.

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(2): 115-130. Nº de citas: 30

    [doi:10.37201/req/158.2021]

  • Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A.

    Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

    Life Science Alliance . 5(4): . Nº de citas: 8

    [doi:10.26508/lsa.202101200]

  • Martínez-Sanz J, Ron R, Moreno E, Sánchez-Conde M, Muriel A, López Cortés LF, Blanco JR, Pineda JA, Mena Á, Calzado Isbert S, Moreno S, Serrano-Villar S.

    Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.

    Frontiers in immunology . 13: 873408-873408. Nº de citas: 2

    [doi:10.3389/fimmu.2022.873408]

  • Albasanz-Puig A, Durà-Miralles X, Laporte-Amargós J, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo JM, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Morales HMP, Brunel AS, García E, Isler B, Kern WV, Retamar-Gentil P, Aguado JM, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmati P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Pallarès N, Bergas A, Carratalà J, Gudiol C, On Behalf Of The Ironic Study Group.

    Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia.

    Microorganisms . 10(4): .

    [doi:10.3390/microorganisms10040733]

  • Moreno S, Alcázar B, Dueñas C, González Del Castillo J, Olalla J, Antela A.

    Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.

    DRUG DESIGN DEVELOPMENT AND THERAPY . 16: 827-841. Nº de citas: 5

    [doi:10.2147/DDDT.S356951]